No alternative? [Power / Sample Size]

posted by mittyri – Russia, 2017-02-10 15:28  – Posting: # 17049
Views: 19,073

Hi ElMaestro,

» Wise words. I think Denmark in the grand scheme of things amounts to very little, and it isn't a market that is particularly appealing to the guys in Armani suits.

Everything could be changed very soon:

Dr Senderovitz added: “The DMA is a committed partner of the EMA, and many of our employees are dedicated members of scientific committees and working groups under the EMA.
“There is no doubt that Brexit will have a major impact on the cooperation on medicinal products throughout Europe, especially because the UK’s Medicines and Healthcare products Regulatory Agency is currently contributing significantly to the scientific work at the EMA.
“Consequently, we are bringing more staff into our organization, and we are willing to take more than a fair share of future assessments. We are also making efforts to strengthen our capacity within scientific advice and biostatistics.”


;-):cool:
Denmark... Why not??

Kind regards,
Mittyri

Complete thread:

Activity
 Admin contact
20,779 posts in 4,351 threads, 1,444 registered users;
online 27 (3 registered, 24 guests [including 16 identified bots]).
Forum time: 13:46 CEST (Europe/Vienna)

All we know about the world teaches us that the effects of A and B
are always different—in some decimal place—for any A and B.
Thus asking “are the effects different?” is foolish.    John W. Tukey

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5